Activin receptor-like kinase-1 compositions and methods of use
AssigneeGenentech, Inc.
InventorsMinhong Yan, Gu Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists.
Claims12
A method of inhibiting lymphangiogenesis comprising administering to a subject in need of inhibition of lymphangiogenesis an effective amount of an ALK-1 immunoadhesin, whereby the lymphangiogenesis is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2, and wherein the subject suffers from a tumor.
A method for treating a pathological condition associated with lymphangiogenesis in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the pathological condition associated with lymphangiogenesis is treated, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2, and whereby the pathological condition associated with lymphangiogenesis is a tumor.
A method of inhibiting tumoral lymphangiogenesis in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumoral lymphangiogenesis is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2.
A method of disrupting pericyte organization in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the pericyte organization is disrupted, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2, and wherein the subject suffers from a tumor.
A method of inhibiting tumor growth in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumor growth is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2.
A method of treating a tumor in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumor is treated, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.